Comparing automated vs manual MRD analysis in AML
Part of Blood & lymphatic, Cancer clinical trials.
This study compares two ways of analyzing flow cytometry data to measure tiny amounts of leukemia left after treatment (called measurable residual disease or MRD). Aim is to see if a computer can do this automatically as well as a human expert, which could help doctors make better treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of acute myeloid leukemia (AML).
- You are either 18 years or older, or you are a child between 0 and 20 years old.
- Your medical information must be stored in the DATAML database (for adults) or pediatric blood cancer records (for children).
- You need to have flow cytometry MRD test results from after your first treatment and after a second treatment (consolidation).
- You must agree (or not object) to your medical data being used for this research.
- You cannot have certain AML subtypes (M3, M6, or M7) or acute leukemia of mixed lineage (MPAL).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for adults with newly diagnosed acute myeloid leukemia (AML) who will receive the drugs azacitidine and venetoclax as their first treatment. Researchers will monitor tiny amounts of cancer left after treatment (MRD) to see how it affects survival.
This trial tests whether adjusting a stem cell transplant (allo-HSCT) based on a marker called MRD (minimal residual disease) improves outcomes for people with a high-risk type of acute myeloid leukemia (AML). It's for those who are newly diagnosed, between 16 and 65, and have early remission after 1 or 2 rounds of chemotherapy.
This study uses a special blood test (flow cytometry) to look for leukemia stem cells in your blood and bone marrow. The goal is to see if these cells can help predict if leukemia will come back after treatment, which might lead to better care for children and teens with AML.
This study uses a special blood test to see if it can predict which patients with a specific type of acute myeloid leukemia (AML with MLL changes) are more likely to relapse or have better survival. The test may help doctors plan better treatment.
This study checks for “minimal residual disease,” meaning tiny numbers of leukemia cells that can remain after treatment. Results may help doctors better monitor your response and risk of relapse in AML or high-risk MDS.
This trial is for people with acute myeloid leukemia (AML) who are in remission but still have tiny traces of leukemia cells that can be found with sensitive tests (called MRD-positive). The study is testing a new treatment approach to try to get rid of those remaining cells and prevent the cancer from coming back.
Hear when a new Leukemia, Myeloid, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.